Cargando…

Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial

Domestic measles, mumps, and rubella combined (MMR) vaccines were discontinued in 1993 in Japan because of the unexpected high incidence of aseptic meningitis. The introduction of an effective MMR vaccine with lower reactogenicity has been expected. A new MMR vaccine (JVC-001) was developed, using m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakayama, Tetsuo, Eda, Masahiro, Hirano, Motonori, Goto, Wakako
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605871/ https://www.ncbi.nlm.nih.gov/pubmed/30724658 http://dx.doi.org/10.1080/21645515.2019.1578591

Ejemplares similares

Response to Measles, Mumps and Rubella (MMR) Vaccine in Transfusion-Dependent Patients
por: Casale, Maddalena, et al.
Publicado: (2021)

Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients
por: Gold, Jeffrey E., et al.
Publicado: (2020)

Are Measles-Mumps-Rubella (MMR) Antibodies Friends or Foes for Covid-19 Disease?
por: Salamony, Azza, et al.
Publicado: (2023)

Anticancer Activity of Measles–Mumps–Rubella MMR Vaccine Viruses against Glioblastoma
por: Khalid, Zumama, et al.
Publicado: (2023)

An Economic Analysis of Mumps Vaccination in Fiji: Static Model Simulation of Routine Measles–Mumps–Rubella (MMR) Vaccination Instead of Current Measles–Rubella (MR) Vaccination
por: Oh, Chunghyeon, et al.
Publicado: (2022)

Seroprevalence of Antibodies to Measles, Mumps, and Rubella among Thai Population: Evaluation of Measles/MMR Immunization Programme
por: Tharmaphornpilas, Piyanit, et al.
Publicado: (2009)

Improving health literacy with mumps, measles and rubella (MMR) vaccination: comparison of the readability of MMR patient-facing literature and MMR scientific abstracts
por: Downey, Tina, et al.
Publicado: (2022)

Recombinant measles AIK-C vaccine strain expressing heterologous virus antigens
por: Nakayama, Tetsuo, et al.
Publicado: (2016)

Recombinant Measles AIK-C Vaccine Strain Expressing Influenza HA Protein
por: Ito, Takashi, et al.
Publicado: (2020)

Missed Opportunities for Measles, Mumps, and Rubella (MMR) Immunization in Mesoamerica: Potential Impact on Coverage and Days at Risk
por: Mokdad, Ali H., et al.
Publicado: (2015)

Measles, Mumps, and Rubella Antibody: Patterns of Persistence and Rate of Decline Following the Second Dose of the MMR Vaccine
por: Seagle, Emma, et al.
Publicado: (2017)

Relationship Between Media Coverage and Measles-Mumps-Rubella (MMR) Vaccination Uptake in Denmark: Retrospective Study
por: Hansen, Niels Dalum, et al.
Publicado: (2019)

2763. Uptake and Safety of Measles-Mumps-Rubella (MMR) Vaccine in Adolescents and Adults in the Vaccine Safety Datalink
por: Hanson, Kayla E, et al.
Publicado: (2019)

A Study to Evaluate the Role of Intradermal and Intralesional Measles, Mumps, Rubella (MMR) Vaccine in Treatment of Common Warts
por: Gupta, Pragya, et al.
Publicado: (2020)

Lessons Learned from Publicizing and Retracting an Erroneous Hypothesis on the Mumps, Measles, Rubella (MMR) Vaccination with Unethical Implications
por: Khan, Hiba, et al.
Publicado: (2021)

Auto-immune thrombocytopenia after Measles Mumps Rubella MMR vaccination: molecular mimicry of measles virus phosphoprotein with platelet gpIIb
por: Tran, Guy Mong Ky, et al.
Publicado: (2010)

Difficulties in Eliminating Measles and Controlling Rubella and Mumps: A Cross-Sectional Study of a First Measles and Rubella Vaccination and a Second Measles, Mumps, and Rubella Vaccination
por: Wang, Zhifang, et al.
Publicado: (2014)

Does Measles, Mumps, and Rubella (MMR) Vaccination Protect against COVID-19 Outcomes: A Nationwide Cohort Study
por: Kolla, Epiphane, et al.
Publicado: (2022)

Characterisation of measles after the introduction of the combined measles-mumps-rubella (MMR) vaccine in 2004 with focus on the laboratory data, 2016 to 2019 outbreak, Romania
por: Lazar, Mihaela, et al.
Publicado: (2019)

Recombinant Measles AIK-C Vaccine Strain Expressing the prM-E Antigen of Japanese Encephalitis Virus
por: Higuchi, Akira, et al.
Publicado: (2016)

Addressing issues of vaccination literacy and psychological empowerment in the measles-mumps-rubella (MMR) vaccination decision-making: a qualitative study
por: Fadda, Marta, et al.
Publicado: (2015)

Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands
por: Tielemans, Susanne M A J, et al.
Publicado: (2017)

571. A Report of the Postmarketing Spontaneous Safety Data over 24 Years for GSK’s Measles-Mumps-Rubella (MMR) Vaccine
por: Singh, Tina, et al.
Publicado: (2022)

Municipality-level measles, mumps, and rubella (MMR) vaccine coverage and deprivation in Brazil: A nationwide ecological study, 2006 to 2020
por: Godin, Audrey, et al.
Publicado: (2023)

AIK-C measles vaccine expressing fusion protein of respiratory syncytial virus induces protective antibodies in cotton rats
por: Sawada, Akihito, et al.
Publicado: (2011)

Measles, Mumps, Rubella serology in juvenile idiopathic arthritis
por: Heijstek, MW, et al.
Publicado: (2008)

Is it time to reconsider measles, mumps, and rubella immunisation strategies?
por: Boccalini, Sara, et al.
Publicado: (2021)

Measles-Mumps-Rubella Vaccine and COVID-19 Relationship
por: Özdemir, Öner
Publicado: (2020)

Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis
por: Schenk, Julie, et al.
Publicado: (2021)

Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines
por: Habib, Md Ahsan, et al.
Publicado: (2023)

Correction to: 571. A Report of the Postmarketing Spontaneous Safety Data over 24 Years for GSK’s Measles-Mumps-Rubella (MMR) Vaccine
Publicado: (2023)

2467. Timeliness of Childhood Vaccination With the Combination Measles–Mumps–Rubella–Varicella Vaccine vs. the Separate Measles–Mumps–Rubella and Varicella Vaccines in the United States
por: Wolfson, Lara, et al.
Publicado: (2018)

Resurgence risk for measles, mumps and rubella in France in 2018 and 2020
por: Béraud, Guillaume, et al.
Publicado: (2018)

Utility of serological screening for measles, mumps and rubella in immunocompromised patients
por: Sticchi, L, et al.
Publicado: (2019)

Inadequate Measles, Mumps, Rubella, and Varicella Immunity Among Employees
por: Ezeji-Okoye, Stephen, et al.
Publicado: (2021)

Knowledge and Practice of Parents Towards Measles, Mumps and Rubella Vaccination
por: Hussein, Siti Zuhaida, et al.
Publicado: (2022)

1077 Adverse events following measles, mumps, and rubella (MMR) vaccine in adults reported to the Vaccine Adverse Event Reporting System, 2003-2013
por: Sukumaran, Lakshmi, et al.
Publicado: (2014)

1339 Measles and Mumps Antibody Response in Young Adults after a Third Dose of Measles-Mumps-Rubella Vaccine
por: Fiebelkorn, Amy Parker, et al.
Publicado: (2014)

Attitudinal and Demographic Predictors of Measles-Mumps-Rubella Vaccine (MMR) Uptake during the UK Catch-Up Campaign 2008–09: Cross-Sectional Survey
por: Brown, Katrina, et al.
Publicado: (2011)

Comparative Study of Efficacy of Intralesional Purified Protein Derivative (PPD) Versus Intralesional Measles, Mumps, and Rubella (MMR) Vaccine in Management of Multiple Viral Warts
por: Bhalala, Krishna B, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jc6nio4ebo3e7k08iphhrf36o9